263 related articles for article (PubMed ID: 24739994)
1. A direct comparison of onabotulinumtoxina (Botox) and IncobotulinumtoxinA (Xeomin) in the treatment of benign essential blepharospasm: a split-face technique.
Saad J; Gourdeau A
J Neuroophthalmol; 2014 Sep; 34(3):233-6. PubMed ID: 24739994
[TBL] [Abstract][Full Text] [Related]
2. Comparison of preferences between onabotulinumtoxinA (Botox) and incobotulinumtoxinA (Xeomin) in the treatment of benign essential blepharospasm.
Chundury RV; Couch SM; Holds JB
Ophthalmic Plast Reconstr Surg; 2013; 29(3):205-7. PubMed ID: 23552607
[TBL] [Abstract][Full Text] [Related]
3. Clinical efficacy and tolerability of Xeomin in the treatment of blepharospasm.
Jankovic J
Eur J Neurol; 2009 Dec; 16 Suppl 2():14-8. PubMed ID: 20002742
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of incobotulinumtoxinA (NT 201, Xeomin) in the treatment of blepharospasm-a randomized trial.
Jankovic J; Comella C; Hanschmann A; Grafe S
Mov Disord; 2011 Jul; 26(8):1521-8. PubMed ID: 21520284
[TBL] [Abstract][Full Text] [Related]
5. Relationship between various clinical outcome assessments in patients with blepharospasm.
Jankovic J; Kenney C; Grafe S; Goertelmeyer R; Comes G
Mov Disord; 2009 Feb; 24(3):407-13. PubMed ID: 19053054
[TBL] [Abstract][Full Text] [Related]
6. A cross-sectional structured survey of patients receiving botulinum toxin type A treatment for blepharospasm.
Fezza J; Burns J; Woodward J; Truong D; Hedges T; Verma A
J Neurol Sci; 2016 Aug; 367():56-62. PubMed ID: 27423565
[TBL] [Abstract][Full Text] [Related]
7. Double-blind, randomised, parallel group pilot study comparing two botulinum toxin type A products for the treatment of blepharospasm.
Wabbels B; Reichel G; Fulford-Smith A; Wright N; Roggenkämper P
J Neural Transm (Vienna); 2011 Feb; 118(2):233-9. PubMed ID: 21161715
[TBL] [Abstract][Full Text] [Related]
8. Re: "Comparison of preferences between onabotulinumtoxinA (Botox) and incobotulinumtoxinA (Xeomin) in the treatment of benign essential blepharospasm".
Giacometti J; Yen MT
Ophthalmic Plast Reconstr Surg; 2014; 30(1):76-7. PubMed ID: 24398499
[No Abstract] [Full Text] [Related]
9. Reply Re: "Comparison of preferences between onabotulinumtoxinA (Botox) and incobotulinumtoxinA (Xeomin) in the treatment of benign essential blepharospasm".
Chundury RV; Couch SM; Holds JB
Ophthalmic Plast Reconstr Surg; 2014; 30(1):77. PubMed ID: 24398500
[No Abstract] [Full Text] [Related]
10. Comparison of Safety and Efficacy of Botox and Neuronox in the Management of Benign Essential Blepharospasm: A Split-face Study.
Sane S; Ali MJ; Naik MN
Korean J Ophthalmol; 2019 Oct; 33(5):430-435. PubMed ID: 31612653
[TBL] [Abstract][Full Text] [Related]
11. Sustained efficacy and safety of repeated incobotulinumtoxinA (Xeomin(®)) injections in blepharospasm.
Truong DD; Gollomp SM; Jankovic J; LeWitt PA; Marx M; Hanschmann A; Fernandez HH;
J Neural Transm (Vienna); 2013 Sep; 120(9):1345-53. PubMed ID: 23435927
[TBL] [Abstract][Full Text] [Related]
12. A guide to dosing in the treatment of cervical dystonia and blepharospasm with Xeomin®: a new botulinum neurotoxin A.
Pagan FL; Harrison A
Parkinsonism Relat Disord; 2012 Jun; 18(5):441-5. PubMed ID: 22405829
[TBL] [Abstract][Full Text] [Related]
13. A comparative crossover study on the treatment of hemifacial spasm and blepharospasm: preseptal and pretarsal botulinum toxin injection techniques.
Lolekha P; Choolam A; Kulkantrakorn K
Neurol Sci; 2017 Nov; 38(11):2031-2036. PubMed ID: 28884242
[TBL] [Abstract][Full Text] [Related]
14. DYSBOT: a single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A--Dysport and Botox--assuming a ratio of 4:1.
Sampaio C; Ferreira JJ; Simões F; Rosas MJ; Magalhães M; Correia AP; Bastos-Lima A; Martins R; Castro-Caldas A
Mov Disord; 1997 Nov; 12(6):1013-8. PubMed ID: 9399229
[TBL] [Abstract][Full Text] [Related]
15. Safety, effectiveness, and duration of effect of BOTOX after switching from Dysport for blepharospasm, cervical dystonia, and hemifacial spasm dystonia, and hemifacial spasm.
Bihari K
Curr Med Res Opin; 2005 Mar; 21(3):433-8. PubMed ID: 15811212
[TBL] [Abstract][Full Text] [Related]
16. IncobotulinumtoxinA (Xeomin®) injected for blepharospasm or cervical dystonia according to patient needs is well tolerated.
Evidente VG; Truong D; Jankovic J; Comella CL; Grafe S; Hanschmann A
J Neurol Sci; 2014 Nov; 346(1-2):116-20. PubMed ID: 25186131
[TBL] [Abstract][Full Text] [Related]
17. Duration and onset of effect of incobotulinumtoxinA for the treatment of blepharospasm in botulinum toxin-naïve subjects.
Mitsikostas DD; Dekundy A; Hanschmann A; Althaus M; Scheschonka A; Pagan F; Jankovic J
Curr Med Res Opin; 2021 Oct; 37(10):1761-1768. PubMed ID: 34384301
[TBL] [Abstract][Full Text] [Related]
18. Prospective, randomized, double-blind study, comparing botulinum toxins type a botox and prosigne for blepharospasm and hemifacial spasm treatment.
Quagliato EM; Carelli EF; Viana MA
Clin Neuropharmacol; 2010; 33(1):27-31. PubMed ID: 20124784
[TBL] [Abstract][Full Text] [Related]
19. Botulinum toxin in blepharospasm and oromandibular dystonia: comparing different botulinum toxin preparations.
Bhidayasiri R; Cardoso F; Truong DD
Eur J Neurol; 2006 Feb; 13 Suppl 1():21-9. PubMed ID: 16417594
[TBL] [Abstract][Full Text] [Related]
20. The influence of benign essential blepharospasm on dry eye disease and ocular inflammation.
Lu R; Huang R; Li K; Zhang X; Yang H; Quan Y; Li Q
Am J Ophthalmol; 2014 Mar; 157(3):591-7.e1-2. PubMed ID: 24269849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]